Allergan Stock Performance in 1Q18

Allergan (AGN) is one of the leading pharmaceutical companies. It deals with both generic and specialty pharmaceutical products. Its headquarters are in Dublin, Ireland. Its US administrative headquarters are in Parsippany, New Jersey. Allergan has segregated its business into three segments: US General Medicine, US Specialized Therapeutics, and International.

The above chart compares Allegan’s revenues and EPS (earnings per share) since 1Q16 and estimates for 1Q18.

Allergan stock fell 6.2% in 1Q18 and has fallen 1.3% year-to-date as of April 6, 2018.

Wall Street analysts estimate that AGN stock has the potential to return 33.7% over the next 12 months. Analysts’ recommendations show a 12-month target price of $215.91 per share compared to the last price of $161.52 per share on April 6, 2018.

There are 25 analysts tracking Allergan stock. Five of them recommend a “strong buy,” 12 recommend a “buy,” and eight recommend a “hold.” The consensus rating for Allergan stands at 2.1, which represents a “buy” for long-term growth investors.

The products that drive Allergan’s growth include medical aesthetics products such as botox, fillers, and Kybella; eye care products, including Restasis and Ozurdex; and general medicines, including Linzess, Lo Loestrin, Viberzi, and Vraylar.

Wall Street analysts estimate revenues of $3.6 billion in 1Q18, a marginal growth of 0.3% compared to 1Q17, and EPS of $3.36.

The iShares US Pharmaceuticals (IHE) holds 5.6% of its total investments in Allergan (AGN), 10.7% in Johnson & Johnson (JNJ), 6.4% in Bristol-Myers Squibb (BMY), and 8.8% in Pfizer (PFE).

Be sure to check out all the data we’ve added to our quote pages. Now you can get a valuation snapshot, earnings and revenue estimates, and historical data, as well as dividend information. Take a look.